| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/22/2003 | EP1276459A1 Cosmetic or dermatological cream composition, the preparation and the use thereof |
| 01/22/2003 | EP1181029B1 Balsam for the treatment of surface burns and chafing rashes |
| 01/22/2003 | EP1079834B1 Stable compositions comprising levosimendan and alginic acid |
| 01/22/2003 | EP0942721B1 Liquid composition comprising an hiv protease inhibitor and a c12-c18 fatty acid |
| 01/22/2003 | EP0854731B1 Copolymeric micelle drug composition and method for the preparation thereof |
| 01/22/2003 | EP0850070B1 Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
| 01/22/2003 | EP0848948B1 Long-lasting composition for rectal administration |
| 01/22/2003 | CN1392900A Alpha-isomaltosylglucosaccharide synthase, process for producing same and use thereof |
| 01/22/2003 | CN1392795A Novel tiotropiumonium-containing inhalation powder |
| 01/22/2003 | CN1391907A Chinese herbal medicine powder using glucose as carrier and its preparing method |
| 01/22/2003 | CN1391889A Tanshinone nano preparation and its preparing method |
| 01/22/2003 | CN1099462C Medical composition |
| 01/21/2003 | US6509451 Cross-linked antibodies and processes for their preparation |
| 01/21/2003 | US6509376 Utilization of dialkyfumarates |
| 01/21/2003 | US6509371 Compositions containing Bergamottin for increasing the oral bioavailability of pharmaceutical agents |
| 01/21/2003 | US6509370 Paclitaxel formulation |
| 01/21/2003 | US6509350 Incorporating stabilizing effective amount of a hydrochloric acid donor to pharmaceutical formulation containing an active component subject to degradation |
| 01/21/2003 | US6509326 Supplements are useful for increasing bone growth and treating age-related bone loss |
| 01/21/2003 | US6509323 Cyclodextrin copolymers may be used as a delivery vehicle of various therapeutic agents |
| 01/21/2003 | US6509319 Chelators have significant growth inhibitory effect against species of Aspergillus |
| 01/21/2003 | US6509040 Active ingredient, modified starch and matrix material; rapid dissolution in mouth; mechanically and chemically stable; delivering higher concentrations |
| 01/21/2003 | US6509038 Antifungal compositions with improved bioavailability |
| 01/21/2003 | US6509036 Effervescence as a penetration enhancer for drugs known, or suspected, of having poor bioavailability. |
| 01/21/2003 | US6509035 Oral preparation of coenzyme a useful for lowering blood lipid and a method producing for same |
| 01/21/2003 | US6509034 Wettable microcapsules having hydrophobic polymer coated cores |
| 01/21/2003 | US6509032 Nontoxic biodegradable derivative of cholesterol having carbamate, ester or amide linker, spacer and primary, tertiary or quaternized amino groups; transfection of nucleic acids into cells |
| 01/21/2003 | US6509029 Mixtures; food, cosmetics, drugs |
| 01/21/2003 | US6509028 Methods and compositions for treating pain of the mucous membrane |
| 01/21/2003 | US6509013 Water insoluble crosslinked allyl amine homo- or copolymer and carrier; removing phosphate from gastrointestinal tract; hyperphosphatemia |
| 01/21/2003 | US6509005 Nonozone depleting stable aerosol; treating nausea and vomiting associated with chemotherapy; muscle spasticity, pain, anorexia associated with AIDS wasting syndrome, epilepsy, glaucoma, bronchial asthma and mood disorders |
| 01/21/2003 | CA2231195C Sustained release matrix for high-dose insoluble drugs |
| 01/21/2003 | CA2205442C Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants |
| 01/21/2003 | CA1341418C Substantially-pure non-inflammatory hyaluronic acid |
| 01/17/2003 | WO2002009717A1 Erectile dysfunction remedies containing prostaglandin derivatives as the active ingredient |
| 01/17/2003 | CA2416709A1 Therapeutic agent for erectile dysfunction containing as the active ingredient prostaglandin derivatives |
| 01/16/2003 | WO2003005636A1 Secure header information for multi-content e-mail |
| 01/16/2003 | WO2003004620A2 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 01/16/2003 | WO2003004590A1 Lanolin substitute, production method thereof and applications of same |
| 01/16/2003 | WO2003004517A2 Peyers's patch and/or m-celle targeting ligands |
| 01/16/2003 | WO2003004466A2 Dye-sulfenates for dual phototherapy |
| 01/16/2003 | WO2003004096A2 Method and composition for prolonging the residence time of drugs in the gut |
| 01/16/2003 | WO2003004070A1 Film-forming compositions for protecting skin from body fluids and articles made therefrom |
| 01/16/2003 | WO2003004065A1 Method of transporting physiological polymer using protein having rxp repeated sequence |
| 01/16/2003 | WO2003004062A1 Pharmaceutical formulations and ligands for use therein; mimetics for uea-1 |
| 01/16/2003 | WO2003004061A1 Uv-screening peptide-flavonoid conjugates |
| 01/16/2003 | WO2003004060A1 Compositions and preparation methods for bioavailable oral aceaceclofenac dosage forms |
| 01/16/2003 | WO2003004048A1 Compositions for nasal administration of insulin |
| 01/16/2003 | WO2003004043A1 Agent containing fat (oil), which contains onion extract, the production and use thereof for caring, preventing or treating damaged skin tissue, especially scarred tissue |
| 01/16/2003 | WO2003004037A1 Xenogenic oligoor/and polyribonucleotides as agents for the treatment of malignant tumours |
| 01/16/2003 | WO2003004005A1 Optimised formulation of tobramycin for aerosolization |
| 01/16/2003 | WO2003004004A1 Pharmacological preparation made from a nanoparticulate mesomorphous polyelectrolyte lipid complex and at least one active ingredient |
| 01/16/2003 | WO2003004001A1 Controlled agglomeration |
| 01/16/2003 | WO2003004000A2 Topical composition for treating pain |
| 01/16/2003 | WO2003003999A2 Delivery of a bioactive material |
| 01/16/2003 | WO2003003979A2 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 01/16/2003 | WO2003003975A2 Detection and therapy of vulnerable plaque with photodynamic compounds |
| 01/16/2003 | WO2003003828A1 Material for improving living environment, and building material, laying material and spraying agent using the same |
| 01/16/2003 | WO2003003806A2 Dye-azide compounds for dual phototherapy |
| 01/16/2003 | WO2002089764A3 Gelatin substitute |
| 01/16/2003 | WO2002085387A3 A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions |
| 01/16/2003 | WO2002085386A3 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
| 01/16/2003 | WO2002085385A3 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa |
| 01/16/2003 | WO2002070590A3 Hydrogel attached to backing and method for making same |
| 01/16/2003 | WO2002067893A3 Pharmaceutical formulation comprising bicalutamide |
| 01/16/2003 | WO2002059147A3 Activatable cytolytic or drug delivery peptides and uses thereof |
| 01/16/2003 | WO2002051301A3 Fullerene (c60)-based x-ray contrast agent for diagnostic imaging |
| 01/16/2003 | WO2002045683A3 Reversible gelling system for ocular drug delivery |
| 01/16/2003 | WO2002043661A3 Recombinant anti-cd30 antibodies and uses thereof |
| 01/16/2003 | WO2002040540A3 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 01/16/2003 | WO2002039955A3 Biodegradable mixed polymeric micelles for drug delivery |
| 01/16/2003 | WO2002038185A3 Injectable sustained release delivery system with loperamide |
| 01/16/2003 | WO2002033044A3 Methods of high-throughput screening for internalizing antibodies |
| 01/16/2003 | WO2002031109A3 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 01/16/2003 | WO2002026782A3 Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| 01/16/2003 | WO2002024150A3 Ultrasonic method and device for wound treatment |
| 01/16/2003 | WO2002022171A3 Pharmaceutical composition having specific water activity |
| 01/16/2003 | WO2002022107A3 Pharmaceutical composition having modified carrier |
| 01/16/2003 | WO2002020047A3 Chlamydial peptides and their mimics in demyelinating disease |
| 01/16/2003 | WO2002016581A3 Compositions and methods for the diagnosis and treatment of tumor |
| 01/16/2003 | WO2001093913A3 T cell receptor fusions and conjugates and methods of use thereof |
| 01/16/2003 | WO2001082972A3 Compositions comprising carriers and transportable complexes |
| 01/16/2003 | WO2001079538A3 Cell-binding nucleic acid molecules (aptamers) |
| 01/16/2003 | US20030014053 Vessel sealing instrument |
| 01/16/2003 | US20030013860 Azalide isomers, water, and acids |
| 01/16/2003 | US20030013857 Crosslinking and immobilizing biomolecules, drugs and synthetic polymers with a thiol or amino reactive group and hydrazino or oxyamino moieties |
| 01/16/2003 | US20030013800 Compositions comprising copolymers of N-vinylcarboxamides and monomers with a hydrophobic radical, and use of these copolymers |
| 01/16/2003 | US20030013759 Injection fatty acid, or salt thereof, into arteries |
| 01/16/2003 | US20030013753 Antiserotonine agents |
| 01/16/2003 | US20030013740 Antidepressants |
| 01/16/2003 | US20030013731 Synergistic mixtures; enhanced absorption |
| 01/16/2003 | US20030013726 Sleep disorders; anxiolytic agents; muscle disease |
| 01/16/2003 | US20030013686 Bisphosphonate compound |
| 01/16/2003 | US20030013683 Using low surface tension lubricant; topical applying |
| 01/16/2003 | US20030013677 Anticancer agents |
| 01/16/2003 | US20030013676 Method and composition for prolonging the residence time of drugs in the gut |
| 01/16/2003 | US20030013674 Gene therapy; in situ supplying of genes; nucleic acid complex |
| 01/16/2003 | US20030013668 Antiarthritic agents; inflammatory bowel disease; multiple sclerosis |
| 01/16/2003 | US20030013666 Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| 01/16/2003 | US20030013653 Mixture with buffer and nonionic surfactant; storage stability |
| 01/16/2003 | US20030013642 Hemoglobin-haptoglobin complexes |